Pipeline

High-profile candidates challenge marketers well in advance of launch
High-profile candidates challenge marketers well in advance of launch
Sony Salzman
April 4, 2018
7:00 pm

With pharma facing ongoing scrutiny of its pricing practices, medical marketers are increasingly asked to demonstrate the superior value of new therapies. High-profile candidates in immunology, pain management, and melanoma challenge marketers well in advance of launch.

The infectious disease doctor mining the microbiome for drugs
The infectious disease doctor mining the microbiome for drugs
Laura Entis
March 15, 2018
4:50 pm

How Seres CEO Roger Pomerantz went from an infectious disease doctor to mining the microbiome for drugs.

New tactics change clinical trial awareness game
New tactics change clinical trial awareness game
Sarah Mahoney
January 17, 2018
12:00 pm

Recruitment for clinical trials has never been easy. New tools and tactics could change that — assuming the sheer volume of information doesn’t overwhelm trial organizers.

The 2018 pipeline report: Aspiring assets to keep an eye on
The 2018 pipeline report: Aspiring assets to keep an eye on
Sony Salzman
December 4, 2017
2:58 pm

The most promising products in pharma’s pipeline will compete in a landscape that increasingly rewards big risks and places an emphasis on novel mechanisms. That comes with a catch.

Novo’s experimental diabetes drug likely to compete with Trulicity
Novo’s experimental diabetes drug likely to compete with Trulicity
Kevin McCaffrey
October 17, 2017
7:17 pm

An FDA advisory committee is scheduled to vote Wednesday on whether to approve Novo’s semaglutide, which, if approved, could steal market share from Eli Lilly’s Trulicity.

Infographic | How often are drugmakers sharing clinical-trial data?
Infographic | How often are drugmakers sharing clinical-trial data?
September 27, 2017
2:50 pm

The answer: it depends on what phase the trial is in.

Collaboration is Key When Solving Cardiovascular Disease
Collaboration is Key When Solving Cardiovascular Disease
John Thero, Amarin
September 7, 2017
2:00 pm

There is a misperception in the U.S. that we have “conquered” heart disease and stroke, but the evidence shows that this is far from true.

Can marketing techniques save clinical trials?
Can marketing techniques save clinical trials?
Larry Dobrow
September 5, 2017
11:00 am

No crucial area in pharma is more desperately in need of a fix — or more stubbornly resistant to change.

Novartis’ CAR-T therapy gets nod from FDA committee
Novartis’ CAR-T therapy gets nod from FDA committee
Jaimy Lee
July 13, 2017
1:55 pm

The drugmaker is one step closer to a potential approval of its experimental cancer treatment.

Merck, Novartis pipeline stunners headline surprisingly good month for CV agents
Merck, Novartis pipeline stunners headline surprisingly good month for CV agents
Kevin McCaffrey
June 28, 2017
1:54 pm

Merck’s CETP inhibitor anacetrapib and Novartis’ monoclonal antibody ACZ885 hit their primary goals in late-stage cardiovascular outcomes trials, both unexpectedly positive results that are heating up this category.

  • From Our Partners